loading
Precedente Chiudi:
$1.17
Aprire:
$1.16
Volume 24 ore:
248.24K
Relative Volume:
0.56
Capitalizzazione di mercato:
$40.11M
Reddito:
-
Utile/perdita netta:
$-35.58M
Rapporto P/E:
-0.4226
EPS:
-2.65
Flusso di cassa netto:
$-42.82M
1 W Prestazione:
-9.52%
1M Prestazione:
-15.56%
6M Prestazione:
+13.43%
1 anno Prestazione:
-39.04%
Intervallo 1D:
Value
$1.09
$1.24
Intervallo di 1 settimana:
Value
$1.09
$1.28
Portata 52W:
Value
$0.808
$3.02

Iterum Therapeutics Plc Stock (ITRM) Company Profile

Name
Nome
Iterum Therapeutics Plc
Name
Telefono
(872) 225-6077
Name
Indirizzo
3 DUBLIN LANDINGS, DUBLIN 1
Name
Dipendente
9
Name
Cinguettio
Name
Prossima data di guadagno
2025-02-07
Name
Ultimi documenti SEC
Name
ITRM's Discussions on Twitter

Confronta ITRM con altri titoli

Azioni Prezzo Cap. di mercato Reddito Reddito netto Flusso di cassa EPS
Biotechnology icon
ITRM
Iterum Therapeutics Plc
1.1334 40.11M 0 -35.58M -42.82M -2.65
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
480.81 125.40B 11.02B -535.60M -978.00M -2.20
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
587.50 65.79B 14.20B 4.41B 3.54B 38.28
Biotechnology icon
ARGX
Argen X Se Adr
559.07 35.18B 2.19B 833.04M -1.28B 12.71
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
244.92 32.67B 2.25B -278.16M -42.59M -2.17
Biotechnology icon
ONC
Beigene Ltd Adr
239.78 26.46B 3.81B -644.79M -669.77M -6.24

Iterum Therapeutics Plc Stock (ITRM) Upgrades & Downgrades

Data Azione Analista Modifica della valutazione
2021-05-28 Aggiornamento Gabelli & Co Sell → Hold
2021-03-15 Aggiornamento H.C. Wainwright Neutral → Buy
2020-06-02 Downgrade RBC Capital Mkts Outperform → Sector Perform
2020-01-21 Downgrade Gabelli & Co Buy → Sell
2019-12-11 Downgrade SVB Leerink Outperform → Mkt Perform
2019-06-21 Iniziato H.C. Wainwright Buy
Mostra tutto

Iterum Therapeutics Plc Borsa (ITRM) Ultime notizie

pulisher
Mar 27, 2025

Sulopenem Etzadroxil/Probenecid (orlynvah) by Iterum - openPR.com

Mar 27, 2025
pulisher
Mar 19, 2025

Iterum outlines ORLYNVAH's market potential with exclusivity through 2034 - MSN

Mar 19, 2025
pulisher
Mar 10, 2025

Iterum Therapeutics appoints Joseph Whalen to its Board By Investing.com - Investing.com Canada

Mar 10, 2025
pulisher
Mar 10, 2025

Iterum Therapeutics appoints Joseph Whalen to its Board - Investing.com

Mar 10, 2025
pulisher
Mar 10, 2025

Iterum Therapeutics Appoints New Board Members - TipRanks

Mar 10, 2025
pulisher
Mar 07, 2025

Sanctuary Advisors LLC Invests $35,000 in Iterum Therapeutics plc (NASDAQ:ITRM) - Defense World

Mar 07, 2025
pulisher
Feb 18, 2025

Iterum Therapeutics plc (NASDAQ:ITRM) Short Interest Down 5.3% in January - Defense World

Feb 18, 2025
pulisher
Feb 14, 2025

Iterum Therapeutics faces Nasdaq non-compliance issue - MSN

Feb 14, 2025
pulisher
Feb 11, 2025

A stock that deserves closer examination: Iterum Therapeutics Plc (ITRM) - US Post News

Feb 11, 2025
pulisher
Feb 10, 2025

Iterum Therapeutics Plc [ITRM] Insider Activity: An Update for Investors - Knox Daily

Feb 10, 2025
pulisher
Feb 10, 2025

ITRM Posts Updates From FDA Advisory Meeting for UTI Drug, Stock Down - MSN

Feb 10, 2025
pulisher
Feb 10, 2025

A better buy-in window may exist right now for Iterum Therapeutics Plc (ITRM) - SETE News

Feb 10, 2025
pulisher
Feb 10, 2025

Iterum Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results -February 10, 2025 at 10:41 am EST - Marketscreener.com

Feb 10, 2025
pulisher
Feb 08, 2025

Iterum Therapeutics plc (NASDAQ:ITRM) Q4 2024 Earnings Call Transcript - Insider Monkey

Feb 08, 2025
pulisher
Feb 08, 2025

Iterum Therapeutics PLC (ITRM) Q4 2024 Earnings Call Highlights: - GuruFocus

Feb 08, 2025
pulisher
Feb 08, 2025

Iterum Therapeutics PLC (ITRM) Q4 2024 Earnings Call Highlights: Navigating Financial ... - Yahoo Finance

Feb 08, 2025
pulisher
Feb 07, 2025

Iterum Therapeutics Highlights FDA Approval and Financial Progress - TipRanks

Feb 07, 2025
pulisher
Feb 07, 2025

Earnings call transcript: Iterum Therapeutics reports Q4 2024 results and stock surges - MSN

Feb 07, 2025
pulisher
Feb 07, 2025

Iterum Therapeutics PLC Files For Mixed Shelf Of Up To $150 Million -February 07, 2025 at 04:42 pm EST - Marketscreener.com

Feb 07, 2025
pulisher
Feb 07, 2025

Iterum Therapeutics Plc’s Shares Reel: 14.34% Quarterly Revenue Decline Amid 40.59M Market Cap - The InvestChronicle

Feb 07, 2025
pulisher
Feb 07, 2025

Iterum Therapeutics PLC reports results for the quarter ended December 31Earnings Summary - TradingView

Feb 07, 2025
pulisher
Feb 07, 2025

Iterum Therapeutics plc Reports Earnings Results for the Fourth Quarter Ended December 31, 2024 - Marketscreener.com

Feb 07, 2025
pulisher
Feb 07, 2025

Iterum Therapeutics plc (ITRM) reports earnings - Quartz

Feb 07, 2025
pulisher
Feb 07, 2025

Iterum Therapeutics plc SEC 10-K Report - TradingView

Feb 07, 2025
pulisher
Feb 07, 2025

ForexTV | Small Business Resources - ForexTV.com

Feb 07, 2025
pulisher
Feb 07, 2025

Iterum Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results - The Manila Times

Feb 07, 2025
pulisher
Feb 07, 2025

Iterum's Landmark UTI Drug ORLYNVAH Powers Financial Turnaround in Q4 Report - StockTitan

Feb 07, 2025
pulisher
Feb 07, 2025

Iterum Therapeutics Plc (ITRM) Shares Down Despite Recent Market Volatility - The News Heater

Feb 07, 2025
pulisher
Feb 06, 2025

Iterum Therapeutics (ITRM) Expected to Announce Quarterly Earnings on Friday - Defense World

Feb 06, 2025
pulisher
Feb 05, 2025

Is Iterum Therapeutics Plc (ITRM) a good investment opportunity? - US Post News

Feb 05, 2025
pulisher
Feb 04, 2025

Iterum Therapeutics to Report Fourth Quarter and Full Year 2024 Financial Results on February 7, 2025 - Marketscreener.com

Feb 04, 2025
pulisher
Jan 31, 2025

Iterum Therapeutics (NASDAQ:ITRM) Stock Quotes, Forecast and News Summary - Benzinga

Jan 31, 2025
pulisher
Jan 31, 2025

Iterum Pharmaceuticals Earnings: Q4 Results and Pipeline Updates Coming February 7 - StockTitan

Jan 31, 2025
pulisher
Jan 01, 2025

Short Interest in Iterum Therapeutics plc (NASDAQ:ITRM) Drops By 10.3% - Defense World

Jan 01, 2025
pulisher
Dec 07, 2024

Iterum Therapeutics to Host Morning Conference Call on U.S. FDA Approval of ORLYNVAH™ (Oral Sulopenem) for the Treatment of Uncomplicated Urinary Tract Infections - The Eastern Progress Online

Dec 07, 2024
pulisher
Dec 02, 2024

Iterum Therapeutics stock hits 52-week high at $2.35 By Investing.com - Investing.com UK

Dec 02, 2024
pulisher
Nov 23, 2024

Metrics That Matter About Iterum Therapeutics Plc (NASDAQ: ITRM) - Stocks Register

Nov 23, 2024
pulisher
Nov 21, 2024

Iterum Therapeutics Regains Full Nasdaq Compliance - The Manila Times

Nov 21, 2024
pulisher
Nov 19, 2024

Iterum Therapeutics to Host Morning Conference Call on U.S. FDA - GuruFocus.com

Nov 19, 2024
pulisher
Nov 15, 2024

Iterum Therapeutics plc Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com

Nov 15, 2024
pulisher
Nov 15, 2024

Iterum Therapeutics plc (NASDAQ:ITRM) Q3 2024 Earnings Call Transcript - Insider Monkey

Nov 15, 2024
pulisher
Nov 15, 2024

Iterum Therapeutics plc (ITRM) Quarterly 10-Q Report - Quartzy

Nov 15, 2024
pulisher
Nov 15, 2024

ARMISTICE CAPITAL, LLC Acquires New Stake in Iterum Therapeutics PLC - GuruFocus

Nov 15, 2024
pulisher
Nov 15, 2024

Iterum Therapeutics PLC (ITRM) Q3 2024 Earnings Call Highlights: Strategic Moves Amid Financial Challenges - GuruFocus.com

Nov 15, 2024
pulisher
Nov 15, 2024

Iterum Therapeutics PLC (ITRM) Q3 2024 Earnings Call Highlights: Strategic Moves Amid Financial ... By GuruFocus - Investing.com Canada

Nov 15, 2024
pulisher
Nov 15, 2024

Iterum Therapeutics PLC (ITRM) Q3 2024 Earnings Call Highlights: Strategic Moves Amid Financial ... - Yahoo Finance

Nov 15, 2024
pulisher
Nov 14, 2024

Iterum Therapeutics’ Strategic Advances with ORLYNVAH Approval - TipRanks

Nov 14, 2024
pulisher
Nov 14, 2024

Earnings Flash (ITRM) ITERUM THERAPEUTICS Reports Q3 Loss $-0.24 - Marketscreener.com

Nov 14, 2024
pulisher
Nov 14, 2024

Iterum Therapeutics Reports Third Quarter 2024 Financial Results - The Manila Times

Nov 14, 2024
pulisher
Nov 14, 2024

Iterum Therapeutics sees cash runway into 2025 - TipRanks

Nov 14, 2024

Iterum Therapeutics Plc Azioni (ITRM) Dati Finanziari

Reddito

loading

Reddito netto

loading

Flusso di cassa

loading

EPS

loading
$66.10
price down icon 2.65%
$73.33
price down icon 0.15%
$31.60
price up icon 0.06%
$18.91
price down icon 11.53%
$92.01
price down icon 1.40%
biotechnology ONC
$264.32
price down icon 7.93%
Capitalizzazione:     |  Volume (24 ore):